FDA chief Hamburg preps for India trip; Questcor taps new CFO; Hungary's Richter eyes a tough 2014;

@FiercePharma: New chief expands Novo team for stepped-up assault on U.S. diabetes market. Story | Follow @FiercePharma

@TracyStaton: Gilead in talks with Indian drugmakers to sell Sovaldi at cut-rate prices. Report | Follow @TracyStaton

@EricPFierce: My colleague Mark Hollmer offers a thoughtful analysis of pacemakers after having one put in. Check it out. More | Follow @EricPFierce

@CarlyHFierce: More Humira sales gains help AbbVie meet forecasts. News | Follow @CarlyHFierce

> FDA Commissioner Margaret Hamburg will jet to India next week to meet with her regulatory counterparts there; the agency recently hired a local man to head up its new office in the country. Release

> Questcor Pharmaceuticals ($QCOR) tapped Rajesh Asarpota as its new chief financial officer, as its current CFO, Michael Murphy, moves into a new job as EVP of strategic affairs and general counsel. Report

> Hungary's Richter posted weak results for the fourth quarter and predicted a decline in revenue and profits for the year ahead. Report

> Embattled Indian drugmaker Ranbaxy Laboratories benefited from sales of two acne drugs in its most recent quarter, narrowing its loss to about $25 million. Report

> Pernix Therapeutics ($PTX) hired former Alvogen CEO Doug Drysdale to take the reins of its company as chairman and CEO, and attracted $65 million in debt financing from an investor consortium led by Athyrium Capital. Release

> Canadian regulators gave Merck & Co. ($MRK) its first approval for a new immunotherapy for grass allergies, Grastek. Release | Report

> Denmark-based Genmab said its leukemia drug Arzerra hit £18.8 million ($30.5 million) in sales for the fourth quarter, with full-year sales at almost £75 million ($122 million); it is expecting a royalty payment from partner GlaxoSmithKline ($GSK). Release

> The founder of New Zealand's biggest drugmaker, Douglas Pharmaceuticals, Sir Graeme Douglas, announced his retirement. Report (sub. req.)

Medical Device News

@FierceMedDev: Edwards wins wider use for older model Sapien heart valve in Europe. More | Follow @FierceMedDev

@MarkHFierce: Thoratec's HeartMate revenue growth is certainly not what it once was. Story | Follow @MarkHFierce

@MichaelGFierce: Check out today's special report: The top drug delivery partnerships of 2013. Report | Follow @MichaelGFierce

@EmilyWFierce: CVS takes cigarettes off the shelf, despite projected dip in profits. Article | Follow @EmilyWFierce

> GE sells off Breas Medical to PBM Capital. More

> Myriad's revenue soars, with further gains expected from $270M Crescendo buy. Story

> Pfizer will use Ichor Medical Systems devices for cancer vaccine development. Item

Biotech News

@FierceBiotech: Purdue launches $12M tit-for-tat fund to seed new biotechs. More | Follow @FierceBiotech

@JohnCFierce: We're seeing a mix of upsized IPO successes with some disappointments as well. Seems the theme for biotech's Q1 biotech. More | Follow @JohnCFierce

@DamianFierce: In the next two years, $GSK expects 6 PhIII readouts and 10 PhIII starts. Release (pdf) | Follow @DamianFierce

@EmilyMFierce: A new strain of avian flu in China has killed one woman and infected at least one another. Story via Washington Post | Follow @EmilyMFierce

> Merck loops Pfizer, Amgen and Incyte in on MK-3475 immunotherapy deal spree. News

> GlaxoSmithKline reloads its pipeline with new PhIII drugs following approvals, setbacks. Story

Drug Delivery News

> The top drug delivery partnerships of 2013. Special Report

> Oramed touts PhIIa insulin pill study results; analysts say 'Prove it.' Story

> Microchip coated with cells gives insight into nanoparticle penetration. Article

> Regulus renews Sanofi microRNA pact to focus on orphan, cancer treatments. Story

> Novo Nordisk taps Zosano's microneedle patch for diabetes drug delivery. News

> Pfizer snags electroporation device license from Ichor for cancer vaccine delivery. News

Diagnostics News

> Israeli team finds that diabetes Dx can also screen for at-risk patients. Story

> Myriad Genetics jumps into RA Dx with its $270M Crescendo Bioscience deal. News

> Loyola team zeroes in on two biomarkers linked to an infant bowel disorder. Article

> Thermo Fisher's revenue climbs as U.S. regulators clear $13.6B Life Tech buy. Story

> NeoGenomics' 22 cancer tests hit the market. Item

> The next possible stroke biomarker might be oxidized LDL. Story

Pharma Marketing News

> Digital agencies use ice cream, quirky tees to woo talent away from rivals. Item

> New chief expands Novo team for stepped-up assault on U.S. diabetes market. News

> How fast can Gilead's hep C star go from zero to $6 billion? Story

> That drug's got personality. But is it 'original,' 'dependable' or both? Article

> As doctors get device-happy, reaching them is a 3-pronged strategy. Story

> UCB nabs Asian marketing rights to hot Biogen MS drugs. News

And Finally... Get more sleep, be more productive. It might boost the economy. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.